NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Forecast, Price & News

$6.85

+0.05 (+0.74%)

(As of 01:57 PM ET)

Compare

Today's Range: $6.73
▼
$7.14
50-Day Range: $5.66
▼
$7.62
52-Week Range: $5.53
▼
$14.97

Volume: 1.35 million shs
Average Volume: 1.91 million shs
Market Capitalization: $1.98 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.57

AbCellera Biologics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 273.9% Upside
$25.57 Price Target
Short Interest: Bearish
13.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.14
Based on 15 Articles This Week
Insider Trading: Acquiring Shares
$1.10 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.57) to ($0.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

579th out of 1,009 stocks

Pharmaceutical Preparations Industry

283rd out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
AbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.57, AbCellera Biologics has a forecasted upside of 273.9% from its current price of $6.84.
Amount of Analyst Coverage
AbCellera Biologics has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
13.52% of the float of AbCellera Biologics has been sold short.
Short Interest Ratio / Days to Cover
AbCellera Biologics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.
Change versus previous month
Short interest in AbCellera Biologics has recently increased by 8.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
AbCellera Biologics does not currently pay a dividend.
Dividend Growth
AbCellera Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABCL.

4.0

News and Social Media Coverage

News Sentiment
AbCellera Biologics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.
Search Interest
67 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 91% compared to the previous 30 days.
MarketBeat Follows
13 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbCellera Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,096,885.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
30.30% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.19% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.57) to ($0.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbCellera Biologics is -38.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbCellera Biologics is -38.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AbCellera Biologics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AbCellera Biologics (NASDAQ:ABCL) Stock

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Stock News Headlines

May 30, 2023 | americanbankingnews.com

AbCellera Biologics Inc. (NASDAQ:ABCL) Short Interest Update

May 29, 2023 | finance.yahoo.com

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

May 30, 2023 | Edge On The Street (Ad)

Is Graphite the New Lithium?

Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.

May 27, 2023 | finance.yahoo.com

Strong week for AbCellera Biologics (NASDAQ:ABCL) shareholders doesn't alleviate pain of one-year loss

May 24, 2023 | markets.businessinsider.com

AbCellera Biologics (ABCL) Gets a Buy from Berenberg Bank

May 24, 2023 | finance.yahoo.com

These Small-Cap Biotech Stocks Have the Wind at Their Back

May 24, 2023 | finance.yahoo.com

UPDATE 1-AbCellera to make C$701 million co-investment in Canada

May 24, 2023 | ca.finance.yahoo.com

AbCellera to make C$701 million co-investment in Canada

May 30, 2023 | Edge On The Street (Ad)

Is Graphite the New Lithium?

May 24, 2023 | finance.yahoo.com

AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients

May 24, 2023 | americanbankingnews.com

AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 7.7%

May 21, 2023 | fool.com

AbCellera Biologics (NASDAQ: ABCL)

May 20, 2023 | americanbankingnews.com

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $25.57 Consensus Price Target from Analysts

May 7, 2023 | seekingalpha.com

AbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call Transcript

May 6, 2023 | finance.yahoo.com

AbCellera Biologics First Quarter 2023 Earnings: EPS Misses Expectations

May 6, 2023 | americanbankingnews.com

AbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $15.00 by Analysts at SVB Securities

May 6, 2023 | msn.com

Credit Suisse Maintains AbCellera Biologics (ABCL) Outperform Recommendation

May 5, 2023 | finance.yahoo.com

Q1 2023 Abcellera Biologics Inc Earnings Call

May 5, 2023 | markets.businessinsider.com

Berenberg Bank Sticks to Their Buy Rating for AbCellera Biologics (ABCL)

May 5, 2023 | finance.yahoo.com

AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript

May 4, 2023 | msn.com

Recap: AbCellera Biologics Q1 Earnings

May 4, 2023 | finance.yahoo.com

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates

May 2, 2023 | americanbankingnews.com

AbCellera Biologics (ABCL) Scheduled to Post Earnings on Thursday

April 27, 2023 | msn.com

Eli Lilly posts Q1 contraction amid hit to COVID sales

April 26, 2023 | americanbankingnews.com

Brokers Issue Forecasts for AbCellera Biologics Inc.'s Q1 2023 Earnings (NASDAQ:ABCL)

April 25, 2023 | msn.com

Unusual Call Option Trade in AbCellera Biologics (ABCL) Worth $27.13K

April 25, 2023 | americanbankingnews.com

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $27.33 Consensus PT from Analysts

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Company Calendar

Last Earnings: 5/04/2023
Today: 5/30/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ABCL
CUSIP: N/A
CIK: 1703057
Web: www.abcellera.com
Phone: 604-559-9005
Fax: N/A
Employees: 386
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.57
High Stock Price Forecast: $34.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +276.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $158.52 million
Net Margins: -27.71%
Pretax Margin: -22.02%
Return on Equity: -4.09%
Return on Assets: -3.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.50
Quick Ratio: 10.50

Sales & Book Value

Annual Sales: $485.42 million
Price / Sales: 4.04
Cash Flow: $0.67 per share
Price / Cash Flow: 10.15
Book Value: $4.31 per share
Price / Book: 1.58

Miscellaneous

Outstanding Shares: 288,730,000
Free Float: 201,243,000
Market Cap: $1.96 billion
Optionable: Not Optionable
Beta: -0.12

Key Executives

Dr. Carl L.G. Hansen Ph.D. (Age 48)
CEO, Pres & Chairperson
Comp: $616.66k

Mr. Andrew Booth M.B.A. (Age 49)
Chief Financial Officer
Comp: $563.57k

Dr. Veronique Lecault Ph.D. (Age 38)
COO & Director
Comp: $563.57k

Mr. Tryn T. Stimart Esq. (Age 53)
J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
Comp: $563.8k

Dr. Ester Falconer Ph.D. (Age 48)
Chief Technology Officer

Mr. Bo Barnhart Ph.D.
Scientific Director

Ms. Tiffany Chiu B.Sc.
Ph.D., VP of Communications

Mr. Murray McCutcheon Ph.D.
Sr. VP of Corp. Devel.

Alexandra Weirich M.Sc.
Mang. of Marketing & Communications

Caitlin Webster CIPD
M.Sc., Sr. Mang. of People & Culture

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABCL Stock - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings or view top-rated stocks.
What is AbCellera Biologics' stock price forecast for 2023?: 8 analysts have issued 1 year price targets for AbCellera Biologics' shares. Their ABCL share price forecasts range from $15.00 to $34.00. On average, they expect the company's stock price to reach $25.57 in the next twelve months. This suggests a possible upside of 276.1% from the stock's current price.
View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts.
How have ABCL shares performed in 2023?: AbCellera Biologics' stock was trading at $10.13 at the start of the year. Since then, ABCL stock has decreased by 32.9% and is now trading at $6.80.
View the best growth stocks for 2023 here.
Are investors shorting AbCellera Biologics?: AbCellera Biologics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 26,620,000 shares, an increase of 8.5% from the April 30th total of 24,530,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is currently 13.5 days. Currently, 13.5% of the shares of the company are sold short.
View AbCellera Biologics' Short Interest.
When is AbCellera Biologics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ABCL earnings forecast.
How were AbCellera Biologics' earnings last quarter?: AbCellera Biologics Inc. (NASDAQ:ABCL) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The business had revenue of $12.20 million for the quarter, compared to the consensus estimate of $12.11 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 4.09% and a negative net margin of 27.71%. The company's revenue was down 96.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.54 earnings per share.
What ETFs hold AbCellera Biologics' stock?: ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), TrueShares Technology, AI & Deep Learning ETF (LRNZ), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), iShares Biotechnology ETF (IBB), Renaissance IPO ETF (IPO) and

When did AbCellera Biologics IPO?: (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.
What is AbCellera Biologics' stock symbol?: AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."
Who are AbCellera Biologics' major shareholders?: AbCellera Biologics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (6.89%), BlackRock Inc. (4.74%), Credit Suisse AG (1.60%), State Street Corp (1.17%), Federated Hermes Inc. (1.01%) and Renaissance Technologies LLC (0.97%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends.
How do I buy shares of AbCellera Biologics?: Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AbCellera Biologics' stock price today?: One share of ABCL stock can currently be purchased for approximately $6.80.
How much money does AbCellera Biologics make?: AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $1.96 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.18) on an earnings per share basis.
How many employees does AbCellera Biologics have?: The company employs 386 workers across the globe.
How can I contact AbCellera Biologics?: The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com.

This page (NASDAQ:ABCL) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AbCellera Biologics (ABCL) Stock Forecast, Price & News

AbCellera Biologics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AbCellera Biologics (NASDAQ:ABCL) Stock

ABCL Stock News Headlines

ABCL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ABCL Stock - Frequently Asked Questions

Overall MarketRank^™